Selective serotonin reuptake inhibitors (SSRIs) are used for the treatment of major depressive and anxiety disorders, and may be used to treat other psychiatric conditions. Citalopram/escitalopram are metabolized by cytochrome P450 2C19 (CYP2C19) and variations in CYP2C19 may affect drug exposure. Compared to extensive metabolizers, CYP2C19 ultrarapid metabolizers may have significantly lower exposure to citalopram/escitalopram while elevated concentrations of these drugs have been observed in poor metabolizers. Therapeutic guidelines for the SSRIs citalopram/escitalopram based on CYP2C19 genotype have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and are available on the PharmGKB website (https://www.pharmgkb.org/guideline/PA166127638).
Experts from the disciplines listed below have tagged this resource as fulfulling genomic competencies.